FDA Rejection Delays Regeneron From Competing With J&J, Pfizer in Multiple Myeloma

Regeneron Pharmaceuticals said the FDA cited no approvability concerns for its multiple myeloma drug, linvoseltamab, other than previously identified issues with a contract manufacturer. While linvoseltamab trails bispecific antibodies currently marketed by Johnson & Johnson and Pfizer, if approved, it could bring patients an earlier treatment option. The post FDA Rejection Delays Regeneron From Competing…

Read More

The Rapidly Evolving Field of Street Medicine

The rapidly evolving field of street medicine — the practice of providing health care to homeless people living outside — is getting a jolt in California with a new player: a medical group devoted exclusively to homeless people. And it’s actually making money. Sachin Jain, who worked on federal Medicaid policy during his tenure in…

Read More